Onco Wiki / Indicación
Primary Mediastinal (Thymic) Large B-Cell Lymphoma · line 1 · Dose-adjusted EPOCH + rituximab (DA-EPOCH-R)
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.
Fuente YAML: registro completo
Notas
STUB — pending Clinical Co-Lead approval. End-of-induction PET-CT визначає чи потрібна consolidation RT (Deauville 4-5 → RT; 1-3 → no RT).
Evidence for specific statements
These citations cover only the statements and scopes shown. They do not establish clinical approval of this record.
The prospective single-group NCI cohort included 51 untreated PMBCL patients. Its reported 93% endpoint is event-free survival during a median five years of follow-up; it must not be labelled progression-free survival or an individual probability of cure.
Endpoint terminology in the cited NCI cohort only; not verification of other response/survival estimates, RT rules, treatment selection or the entire indication.
SRC-DUNLEAVY-PMBCL-DAEPOCH-2013
Dunleavy 2013 primary abstract: Methods and Results.
Utilizado por
Algoritmos
ALGO-PMBCL-1L - ALGO-PMBCL-1L